<DOC>
	<DOC>NCT00080509</DOC>
	<brief_summary>The purpose of this study is to determine whether a potential drug known as KOS-862 or "Epothilone D" has an effect as a 2nd line treatment in non-small cell lung cancer (NSCLC) for patients having failed one prior platinum-containing chemotherapy regimen.</brief_summary>
	<brief_title>Effectiveness of KOS-862 in the Treatment of Lung Cancer</brief_title>
	<detailed_description>To determine the antitumor activity, based on the confirmed objective response rate, of KOS-862, administered intravenously weekly for 3 weeks every 4 weeks, in patients with non-small cell lung cancer (NSCLC) whose disease has progressed following initial chemotherapy for advanced or metastatic disease.</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<criteria>At least 18 years of age Measurable disease One previous treatment of a platinum based drug such as cisplatin or carboplatin At least 3 weeks since last surgery/radiation/chemotherapy Brain metastases Changes in the rhythm of your heart that are considered significant as determined by an ECG tracing</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2009</verification_date>
</DOC>